Malignant gliomas in adults.
暂无分享,去创建一个
[1] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[2] L. Deangelis,et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma , 2009, Neurology.
[3] R. McLendon,et al. Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma , 2009, Cancer.
[4] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[5] S. Nelson,et al. Bevacizumab and chemotherapy for recurrent glioblastoma , 2009, Neurology.
[6] R. Jain,et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer , 2009, Nature Reviews Clinical Oncology.
[7] Allan H Friedman,et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Masahiro Inoue,et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.
[9] John A Butman,et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Wen. New developments in targeted molecular therapies for glioblastoma , 2009, Expert review of anticancer therapy.
[11] Henry Brem,et al. Central nervous system cancers. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.
[12] Caterina Giannini,et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Wen,et al. Novel anti-angiogenic therapies for malignant gliomas , 2008, The Lancet Neurology.
[14] P. Wen,et al. Antiangiogenic therapy in malignant gliomas , 2008, Current opinion in oncology.
[15] L. Ellis,et al. Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy , 2008, Clinical Cancer Research.
[16] D. Bigner,et al. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. , 2008, Seminars in immunology.
[17] Denis Lacombe,et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[19] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[20] K. Hoang-Xuan,et al. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. , 2008, The oncologist.
[21] J. Herman,et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[23] T. Cloughesy,et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. , 2008, International journal of radiation oncology, biology, physics.
[24] Susan M. Chang,et al. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. , 2008, Neuro-oncology.
[25] K. Aldape,et al. Molecular predictors in glioblastoma: toward personalized therapy. , 2008, Archives of neurology.
[26] D. Rowitch,et al. Glioma Stem Cells: A Midterm Exam , 2008, Neuron.
[27] E. Domany,et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P. Dirks,et al. Brain tumor stem cells: bringing order to the chaos of brain cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] D. Bigner,et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM , 2008 .
[30] G. Johnson,et al. Bevacizumab therapy in recurrent high grade glioma: Impact on local control and survival , 2008 .
[31] T. Mikkelsen,et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) , 2008 .
[32] P. Gutin,et al. Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM) , 2008 .
[33] W. Mason,et al. The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma , 2008 .
[34] T. Mikkelsen,et al. Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan , 2008 .
[35] H. Friedman,et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas , 2008 .
[36] Dieta Brandsma,et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.
[37] M. Berger,et al. GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME , 2008, Neurosurgery.
[38] P. Wen,et al. Bevacizumab for recurrent malignant gliomas , 2008, Neurology.
[39] Veit Rohde,et al. EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME: IDENTIFICATION OF AND ADJUSTMENT FOR BIAS , 2008, Neurosurgery.
[40] S. Horvath,et al. Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.
[41] T. MacDonald,et al. Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report , 2007, Clinical Cancer Research.
[42] M. Bent. Anaplastic oligodendroglioma and oligoastrocytoma. , 2007 .
[43] P. Wen,et al. Inhibition of angiogenesis and invasion in malignant gliomas , 2007, Expert review of anticancer therapy.
[44] D. Gutmann,et al. Cancer stem cells and brain tumors: uprooting the bad seeds , 2007, Expert review of anticancer therapy.
[45] S. Plotkin,et al. Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. , 2007, Neurologic clinics.
[46] Volker W Stieber,et al. Advances in radiation therapy for brain tumors. , 2007, Neurologic clinics.
[47] D. Reardon,et al. Diagnosis and treatment of high-grade astrocytoma. , 2007, Neurologic clinics.
[48] N. Pouratian,et al. Advances in brain tumor surgery. , 2007, Neurologic clinics.
[49] Margaret Wrensch,et al. Epidemiology of brain tumors. , 2007, Neurologic clinics.
[50] Geoffrey S Young,et al. Advanced MRI of adult brain tumors. , 2007, Neurologic clinics.
[51] L. Chin,et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.
[52] John Sampson,et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] E. Linos,et al. Atopy and risk of brain tumors: a meta-analysis. , 2007, Journal of the National Cancer Institute.
[54] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[55] Robert T Abraham,et al. Targeting the mTOR signaling network in cancer. , 2007, Trends in molecular medicine.
[56] R. Gilbertson,et al. Making a tumour's bed: glioblastoma stem cells and the vascular niche , 2007, Nature Reviews Cancer.
[57] J. Rich,et al. Cancer stem cells in radiation resistance. , 2007, Cancer research.
[58] Christopher G Willett,et al. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Mark R Gilbert,et al. Chemoradiotherapy in malignant glioma: standard of care and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] L. Leibovici,et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. , 2007, Mayo Clinic proceedings.
[61] S. Shete,et al. GLIOGENE—an International Consortium to Understand Familial Glioma , 2007, Cancer Epidemiology Biomarkers & Prevention.
[62] Wei Chen. Clinical Applications of PET in Brain Tumors* , 2007, Journal of Nuclear Medicine.
[63] N. Curtin,et al. PARP inhibitor development for systemic cancer targeting. , 2007, Anti-cancer agents in medicinal chemistry.
[64] G. Reifenberger,et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] A. Gregory Sorensen,et al. Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.
[66] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[67] D. Reardon,et al. Molecularly targeted therapy for malignant glioma , 2007, Cancer.
[68] P. Wen,et al. A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma , 2007 .
[69] Li Zhang,et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] V. Collins,et al. Mechanisms of Disease: genetic predictors of response to treatment in brain tumors , 2007, Nature Clinical Practice Oncology.
[71] Alexander Brawanski,et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. , 2007, Cancer research.
[72] P. Kleihues,et al. Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.
[73] P. Wen,et al. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. , 2007, Journal of the National Cancer Institute.
[74] Anssi Auvinen,et al. Mobile phone use and risk of glioma in 5 North European countries , 2007, International journal of cancer.
[75] D. Hicklin,et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. , 2007, Cancer research.
[76] Luc Taillandier,et al. Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.
[77] Kjell Hansson Mild,et al. Long-term use of cellular phones and brain tumours: increased risk associated with use for ⩾10 years , 2007, Occupational and Environmental Medicine.
[78] M. Lesniak,et al. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. , 2007, Current drug delivery.
[79] P. Wen,et al. Inhibiting kinases in malignant gliomas , 2007, Expert opinion on therapeutic targets.
[80] Darell D. Bigner,et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.
[81] Hongye Liu,et al. Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma , 2007, Neuron.
[82] G. Fulci,et al. The status of gene therapy for brain tumors , 2007, Expert opinion on biological therapy.
[83] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[84] I. Bayazitov,et al. A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.
[85] D. Louis. WHO classification of tumours of the central nervous system , 2007 .
[86] R. McLendon,et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas , 2007, Journal of Neuro-Oncology.
[87] Mark W. Dewhirst,et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.
[88] K. Black,et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.
[89] C. Marras,et al. Glioblastoma‐derived tumorospheres identify a population of tumor stem‐like cells with angiogenic potential and enhanced multidrug resistance phenotype , 2006, Glia.
[90] S. Gabriel,et al. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain , 2006, PLoS medicine.
[91] E. Shaw,et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.
[92] A. Brandes,et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] A. Brandes,et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.
[94] Howard A. Fine,et al. Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.
[95] Qiulian Wu,et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.
[96] M. Gonda,et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] Susan M. Chang,et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] S. Kesari,et al. The Bad Seed: PDGF Receptors Link Adult Neural Progenitors to Glioma Stem Cells , 2006, Neuron.
[99] P. Wen,et al. Medical management of patients with brain tumors , 2006, Journal of Neuro-Oncology.
[100] M. Assanah,et al. Glial Progenitors in Adult White Matter Are Driven to Form Malignant Gliomas by Platelet-Derived Growth Factor-Expressing Retroviruses , 2006, The Journal of Neuroscience.
[101] Walter Curran,et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] Denis Lacombe,et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] B. Fox,et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer , 2006, Cancer Gene Therapy.
[104] Angelo L. Vescovi,et al. Brain tumour stem cells , 2006, Nature Reviews Cancer.
[105] F. Zanella,et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.
[106] T. Cloughesy,et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006, Neurology.
[107] K. Aldape,et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. , 2006, Cancer research.
[108] M. Clarke,et al. Stem Cells and Cancer: Two Faces of Eve , 2006, Cell.
[109] E. Shaw,et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] Susan M. Chang,et al. Diagnosis and treatment of recurrent high-grade astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] D. Gerber,et al. Management of venous thromboembolism in patients with primary and metastatic brain tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] Thomas D. Wu,et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.
[113] S. Cha,et al. Update on brain tumor imaging: from anatomy to physiology. , 2006, AJNR. American journal of neuroradiology.
[114] E. Holland,et al. Platelet-derived growth factor (PDGF) and glial tumorigenesis. , 2006, Cancer letters.
[115] R. Martuza,et al. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. , 2006, Journal of the National Cancer Institute.
[116] A. Verma. MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .
[117] R. Coleman,et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[118] V. Levin,et al. Headache related to brain tumors , 2006, Current treatment options in neurology.
[119] Z. Ram,et al. Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial , 2006, Acta Neurochirurgica.
[120] Allan H Friedman,et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] J. Debus,et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[123] Ricky T. Tong,et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] M. Berger,et al. Biomarkers to Predict Response to Epidermal Growth Factor Receptor Inhibitors , 2005, Cell cycle.
[125] R. Arusell,et al. A Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas: The Impact of the Extent of Resection on Quality of Life and Survival , 2005, Neurosurgery.
[126] J. Flickinger,et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. , 2005, International journal of radiation oncology, biology, physics.
[127] Mitchel S Berger,et al. Neural stem cells and the origin of gliomas. , 2005, The New England journal of medicine.
[128] B. Scheithauer,et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[129] Susan M. Chang,et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.
[130] M. Andreeff,et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. , 2005, Cancer research.
[131] Michael Dean,et al. Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.
[132] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[133] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[134] M. Vogelbaum,et al. Results of a Survey of Neurosurgical Practice Patterns Regarding the Prophylactic use of Anti-Epilepsy Drugs in Patients with Brain Tumors , 2005, Journal of Neuro-Oncology.
[135] Maria Werner-Wasik,et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. , 2004, International journal of radiation oncology, biology, physics.
[136] Caterina Giannini,et al. Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance , 2004, Journal of neuropathology and experimental neurology.
[137] E. Bruera,et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[138] E. Laws,et al. Depression in Patients with High-grade Glioma: Results of the Glioma Outcomes Project , 2004, Neurosurgery.
[139] Susan M. Chang,et al. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. , 2004, Journal of neurosurgery.
[140] M. Gilbert,et al. Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. , 2004, Neuro-oncology.
[141] Allan H Friedman,et al. Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[142] M. Prins,et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.
[143] E. Maher,et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[144] S. Spencer,et al. Role of Radiation Therapy and Radiosurgery in Glioblastoma Multiforme , 2003, Cancer journal.
[145] L. Recht,et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas , 2003, Cancer.
[146] W. Cavenee,et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. , 2003, The American journal of pathology.
[147] Z. Ram,et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.
[148] T. Golub,et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.
[149] A. Tolcher,et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.
[150] M. Westphal,et al. Invasion as limitation to anti-angiogenic glioma therapy. , 2003, Acta neurochirurgica. Supplement.
[151] J. Olson,et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. , 2002, Neurosurgery.
[152] J. Olson,et al. The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine , 2002, Neurosurgery.
[153] L. Stewart,et al. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.
[154] G. Reifenberger,et al. The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.
[155] M. Westphal,et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.
[156] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[157] Z L Gokaslan,et al. Limitations of stereotactic biopsy in the initial management of gliomas. , 2001, Neuro-oncology.
[158] R. DePinho,et al. Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.
[159] R A Betensky,et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[160] A. Brandes,et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. , 2001, Annals of Oncology.
[161] M Brada,et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[162] M. member. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. , 2001 .
[163] P. Black,et al. Cellular-telephone use and brain tumors. , 2001, The New England journal of medicine.
[164] H. Engelhard,et al. Gene therapy for brain tumors , 2000, Current oncology reports.
[165] D. Osoba,et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.
[166] M. Westphal,et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.
[167] D. Louis,et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. , 2000, Journal of neurosurgery.
[168] L. Recht,et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors , 2000, Neurology.
[169] Susan M. Chang,et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[170] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[171] G. Yancopoulos,et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.
[172] M. Westphal,et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis , 1999, International journal of cancer.
[173] M. Martel,et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. , 1999, International journal of radiation oncology, biology, physics.
[174] D. Louis,et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.
[175] V. Levin,et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[176] D. Louis,et al. SPECIFIC CHROMOSOMAL LOSSES PREDICT CHEMOTHERAPEUTIC RESPONSE AND SURVIVAL IN PATIENTS WITH ANAPLASTIC OLIGODENDROGLIOMAS , 1998 .
[177] W. K. Alfred Yung,et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.
[178] A. Hopkins,et al. Malignant cerebral glioma—I: Survival, disability, and morbidity after radiotherapy , 1996, BMJ.
[179] Y. Yonekawa,et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. , 1996, Brain pathology.
[180] D. Louis,et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.
[181] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.
[182] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. , 1995, Lancet.
[183] A. Ullrich,et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.
[184] P. Graham. Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.
[185] P. Wen,et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors , 1993, Neurology.
[186] D. Nelson,et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.
[187] H. Fine,et al. Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.
[188] Georg Breier,et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.
[189] S. Weiss,et al. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. , 1992, Science.
[190] D. Stefanik,et al. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. , 1991, Cancer research.
[191] R. Ruff,et al. Incidence and treatment of peripheral venous thrombosis in patients with glioma , 1983, Annals of neurology.
[192] K. Takakura,et al. [Epidemiology of brain tumors (author's transl)]. , 1982, No to shinkei = Brain and nerve.
[193] Fred H. Hochberg,et al. Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.
[194] E. Alexander,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.
[195] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.